Browse > Article
http://dx.doi.org/10.3345/kjp.2008.51.2.204

Change of neutrophil count after treatment of intravenous immunoglobulin in children with idiopathic thrombocytopenic purpura  

Park, Jun Young (Department of Pediatrics, Pusan National University College of Medicine)
Park, Ji Ae (Department of Pediatrics, Pusan National University College of Medicine)
Park, Seong Shik (Department of Pediatrics, Pusan National University College of Medicine)
Lim, Young Tak (Department of Pediatrics, Pusan National University College of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.51, no.2, 2008 , pp. 204-208 More about this Journal
Abstract
Purpose : The aim of this study was to investigate the incidence and course of neutropenia following intravenous immunoglobulin (IVIG) therapy in children with idiopathic thrombocytopenic purpura (ITP). Methods : From January 2001 to June 2006, fifty-four patients with ITP were enrolled in this study. Forty-two of 54 patients were treated with IVIG, while the other 12 were treated with anti-D immunoglobulin (Anti-D Ig). Post-treatment absolute neutrophil counts (ANC) were compared between patients who received IVIG and those who received Anti-D Ig. Comparison of post-treatment ANC between patients who treated with two different IVIG regimens (400 mg/kg/day for 5 days and 1 g/kg/day for 2 days) was also performed. Results : Pretreatment ANC were not significantly different between the two treatment groups. After treatment with IVIG, 32 out of 42 patients (76.2%) showed more than 50% decrease of ANC from the baseline. On the other hand, only 2 out of 12 patients (16.7%) showed more than 50% decrease of ANC from the baseline after treatment Anti-D Ig. No significant difference was observed in the decline of ANC between the first IVIG treatment (42 patients) and repeated IVIG treatment groups (7 patients). There was no statistical difference in post-treatment ANC between patients who treated with two different IVIG regimens. The neutropenia induced by IVIG had resolved spontaneously in 38 out of 39 patients (97%) after several days. Conclusion : Neutropenia following IVIG administration may not be an uncommon finding in children with ITP. It seems to be transient and self limited.
Keywords
Neutropenia; Intravenous immunoglobulin; Idiopathic thrombocytopenic purpura;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lightsey AL, Koenig HM, McMillan R, Stone JR. Platelet-associated immunoglobulin G in childhood idiopathic thrombocytopenic purpura. J Pediatr 1979;94:201-4   DOI
2 Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-31
3 Ryan ME, Webster ML, Statler JD. Adverse effects of intravenous immunoglobulin therapy. Clin Pediatr(Phila) 1996;35:23-31   DOI   ScienceOn
4 Niebanck AE, Kwiatkowski JL, Raffini LJ. Neutropenia following IVIG therapy in pediatric patients with immunemediated thrombocytopenia. J Pediatr Hematol Oncol 2005;27:145-7   DOI   ScienceOn
5 Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-92   DOI   ScienceOn
6 Lassiter HA, Bibb KW, Bertolone SJ, Patel CC, Stroncek DF. Neonatal immune neutropenia following the administration of intravenous immune globulin. Am J Pediatr Hematol Oncol 1993;15:120-3   DOI   ScienceOn
7 Sugita K, Eguchi M. Suppressive effect of intravenous immunoglobulin on peripheral blood neutrophil count in patients with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2005;27:7-10   DOI   ScienceOn
8 NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 1990;264:3189-93   DOI
9 Schulman I. Diagnosis and treatment: management of idiopathic thrombocytopenic purpura. Pediatrics 1964;33:979-80
10 Simmons SM, Main CA, Yaish HM, Rutzky J. Idiopathic thrombocytopenic purpura in child. J Pediatr 1975;87:16-22   DOI
11 Berkovitch M, Dolinski G, Tauber T, Aladjem M, Kaplinsky C. Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. Int J Immunopharmacol 1999;21:411-5   DOI   ScienceOn
12 Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994;97(Suppl 1):79-83
13 Altznauer F, von Gunten S, Spath P, Simon HU. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 2003;112:1185-90   DOI   ScienceOn
14 Lusher JM, Zuelzer WW. Idiopathic thrombocytopenic purpura in child. J Pediatr 1966;68:971-9   DOI
15 Tsujimoto H, Takeshita S, Nakatani K, Kawamura Y, Tokutomi T, Sekine I. Intravenous immunoglobulin therapy induces neutrophil apoin kawasaki disease. Clin Immunol 2002;103:161-8   DOI   ScienceOn
16 Walker RW, Walker W. Idiopathic thrombocytopenia, initial illness and long term follow up. Arch Dis Child 1984;59:316-22   DOI   ScienceOn
17 Tam DA, Morton LD, Stroncek DF, Leshner RT. Neutropenia in a patient receiving intravenous immune globulin. J Neuroimmunol 1996;64:175-8   DOI   ScienceOn
18 McElfresh AE. Idiopathic thrombocytopenic purpura--to treat or not to treat? J Pediatr 1975;87:160-1   DOI
19 Veys PA, Macey MG, Owens CM, Newland AC. Neutropenia following intravenous immunoglobulin. Br Med J 1988;296:1800
20 Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 1986;314:1236-9   DOI   ScienceOn